Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change Price Change
grade A 73.18 2.58% 1.84
ABBV closed up 2.58 percent on Thursday, June 22, 2017, on 1.7 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ABBV trend table...

Date Alert Name Type % Chg
Jun 22 New 52 Week High Bullish 0.00%
Jun 22 Wide Range Bar Range Expansion 0.00%
Jun 22 Expansion Breakout Bullish Swing Setup 0.00%
Jun 20 New 52 Week High Bullish 2.75%
Jun 19 New 52 Week High Bullish 2.58%

Older signals for ABBV ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.
Is ABBV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 73.67
52 Week Low 54.5176
Average Volume 5,848,675
200-Day Moving Average 62.9307
50-Day Moving Average 66.8962
20-Day Moving Average 68.9695
10-Day Moving Average 70.812
Average True Range 0.9411
ADX 45.94
+DI 44.05
-DI: 5.84
Chandelier Exit (Long, 3 ATRs) 70.8467
Chandelier Exit (Short, 3 ATRs) 68.2533
Upper Bollinger Band 73.1908
Lower Bollinger Band 64.7482
Percent B (%b) 1.0
Bandwidth 0.122411
MACD Line 1.5612
MACD Signal Line 1.2454
MACD Histogram 0.3158